Sun H, Zhao Q, Wang Y, Lakin R, Feng H, Fan X, Luo H, Gao D, Liu L, He Y, Yang P. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report.
Medicine (Baltimore) 2018;
97:e9670. [PMID:
29369185 PMCID:
PMC5794369 DOI:
10.1097/md.0000000000009670]
[Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
RATIONALE
Left ventricular non-compaction cardiomyopathy (LVNC) is a rare heart disorder related to thrombosis. Anticoagulant therapy is suggested for the treatment of this disease. The success of the novel oral anticoagulant rivaroxaban as a treatment option for this disorder is unclear.
PATIENT CONCERNS
A 43-year-old man who felt dizzy at rest was found to have an intraventricular thrombus.
DIAGNOSES
The thrombus was confirmed by echocardiography. And LVNC was diagnosed by cardiac magnetic resonance (CMR) and echocardiography.
INTERVENTIONS
He was prescribed a low dose (10 mg daily) of rivaroxaban as treatment.
OUTCOMES
After 3 months, the thrombus diminished, and the manifestation disappeared.
LESSONS
Low dose of rivaroxaban may serve as a viable option for anticoagulation therapy in LVNC patients, with large clinical trials needed to determine the best course of treatment.
Collapse